IL192890A0 - Novel spiro [imidazolidine-4,3'-indole]2,2" , 5' (ih)-triones for treatment of conditions associated with vanilloid receptor 1 - Google Patents

Novel spiro [imidazolidine-4,3'-indole]2,2" , 5' (ih)-triones for treatment of conditions associated with vanilloid receptor 1

Info

Publication number
IL192890A0
IL192890A0 IL192890A IL19289008A IL192890A0 IL 192890 A0 IL192890 A0 IL 192890A0 IL 192890 A IL192890 A IL 192890A IL 19289008 A IL19289008 A IL 19289008A IL 192890 A0 IL192890 A0 IL 192890A0
Authority
IL
Israel
Prior art keywords
triones
imidazolidine
indole
treatment
conditions associated
Prior art date
Application number
IL192890A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Tomaszewski Miroslaw
Leung Carmen
Woo Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL192890(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Tomaszewski Miroslaw, Leung Carmen, Woo Simon filed Critical Astrazeneca Ab
Publication of IL192890A0 publication Critical patent/IL192890A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
IL192890A 2006-02-07 2008-07-17 Novel spiro [imidazolidine-4,3'-indole]2,2" , 5' (ih)-triones for treatment of conditions associated with vanilloid receptor 1 IL192890A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
PCT/SE2007/000107 WO2007091947A2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1

Publications (1)

Publication Number Publication Date
IL192890A0 true IL192890A0 (en) 2009-02-11

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192890A IL192890A0 (en) 2006-02-07 2008-07-17 Novel spiro [imidazolidine-4,3'-indole]2,2" , 5' (ih)-triones for treatment of conditions associated with vanilloid receptor 1

Country Status (21)

Country Link
US (2) US20070185179A1 (https=)
EP (1) EP2013215A4 (https=)
JP (1) JP2009526043A (https=)
KR (1) KR20080094906A (https=)
CN (1) CN101415711A (https=)
AR (1) AR059265A1 (https=)
AU (1) AU2007212786B2 (https=)
BR (1) BRPI0707423A2 (https=)
CA (1) CA2641632A1 (https=)
CL (1) CL2009000523A1 (https=)
IL (1) IL192890A0 (https=)
NO (1) NO20083547L (https=)
NZ (1) NZ571070A (https=)
RU (1) RU2421457C2 (https=)
SA (1) SA07280027B1 (https=)
SG (1) SG169387A1 (https=)
TW (1) TW200801011A (https=)
UA (1) UA93226C2 (https=)
UY (1) UY30132A1 (https=)
WO (1) WO2007091947A2 (https=)
ZA (1) ZA200806407B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
HUP0203548A3 (en) * 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
US7879866B2 (en) 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
WO2007091948A2 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Also Published As

Publication number Publication date
SA07280027B1 (ar) 2010-11-22
AU2007212786A1 (en) 2007-08-16
AU2007212786A8 (en) 2010-05-06
NZ571070A (en) 2011-07-29
WO2007091947A8 (en) 2008-08-07
AU2007212786B2 (en) 2011-06-02
RU2008131905A (ru) 2010-03-20
EP2013215A2 (en) 2009-01-14
US7868181B2 (en) 2011-01-11
ZA200806407B (en) 2009-04-29
CN101415711A (zh) 2009-04-22
EP2013215A4 (en) 2010-09-08
CL2009000523A1 (es) 2009-07-17
BRPI0707423A2 (pt) 2011-05-03
RU2421457C2 (ru) 2011-06-20
NO20083547L (no) 2008-11-05
WO2007091947A3 (en) 2007-10-04
SG169387A1 (en) 2011-03-30
KR20080094906A (ko) 2008-10-27
JP2009526043A (ja) 2009-07-16
TW200801011A (en) 2008-01-01
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
US20090137650A1 (en) 2009-05-28
AR059265A1 (es) 2008-03-19
WO2007091947A2 (en) 2007-08-16
UA93226C2 (en) 2011-01-25
US20070185179A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
ZA200708490B (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrole
HUS1700010I1 (hu) Új vegyületek mint ópioid receptor modulátorok
SI1725567T1 (sl) Spirociklični cikloheksanski derivati z afiniteto za ORL1 receptor
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
ZA200700684B (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
PL2418201T3 (pl) Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego
IL197034A0 (en) Method for synthesis of 8-alkoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones
IL192890A0 (en) Novel spiro [imidazolidine-4,3'-indole]2,2" , 5' (ih)-triones for treatment of conditions associated with vanilloid receptor 1
EP2023735A4 (en) USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
HK1126209A (en) Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1
GB0516603D0 (en) Processes for the preparation of organic compounds useful as serotonin receptor antagonists
HK1125941A (en) Novel spiro [imidazolidine-4, 3'-indole] 2, 2',5'(1h) triones for treatment of conditions associated with vanilloid receptor 1
HK1123799A (en) Use of spiro [ imidazolidine-4, 3'-indole] 2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1
ZA201007519B (en) Spiro (piperidine-4, 2' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
IL212473A0 (en) Use of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino [4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
WO2009130710A3 (en) A process for the preparation of paliperidone intermediates
ZA200709814B (en) Process for the production of intermediates for the preparation of tricyclic benzimidazoles
IL181721A0 (en) Process for preparing bicyclic pyrazolyl compounds
HK1131390A (en) Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
IL194384A0 (en) Process for preparaing 6,7-dihydro-5h-imidazo[1,5-a]pyridin-8-one
EP2020411A4 (en) TETRACYCLIC SPIRO COMPOUND
HK1109890A (en) Pyrrolinidium derivatives as m3 muscarinic receptors
HK1141716A (en) Therapeutic use of anti-tweak receptor antibodies
HK1096094A (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
HK1157570A (en) Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol